Provided by Tiger Fintech (Singapore) Pte. Ltd.

CRISPR Therapeutics AG

43.31
-0.5300-1.21%
Post-market: 43.03-0.2800-0.65%19:00 EST
Volume:1.28M
Turnover:54.70M
Market Cap:3.71B
PE:-9.98
High:43.74
Open:42.57
Low:41.53
Close:43.84
Loading ...

CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade

Zacks
·
15 Jan

Editas Medicine Outlines 2025 Strategic Priorities and Milestones

TipRanks
·
14 Jan

Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts

Motley Fool
·
14 Jan

Buy Rating for Crispr Therapeutics AG: Strong Pipeline, Strategic Partnerships, and Financial Stability Drive Confidence

TIPRANKS
·
14 Jan

Press Release: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Dow Jones
·
13 Jan

Crispr Therapeutics Highlights Strategic Priorities And Anticipated 2025 Milestones

Reuters
·
13 Jan

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones

GlobeNewswire
·
13 Jan

Catherine Wood's Recent Transaction with CRISPR Therapeutics AG

GuruFocus
·
11 Jan

3 Mid-Cap Stocks That Could Take Off in 2025

Motley Fool
·
09 Jan

CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note

Zacks
·
08 Jan

BofA Securities Adjusts Price Target on CRISPR Therapeutics to $85 From $98, Maintains Buy Rating

MT Newswires Live
·
07 Jan

CRISPR Therapeutics Ag : Bofa Global Research Cuts Price Objective to $85 From $98

THOMSON REUTERS
·
07 Jan

Crispr Therapeutics proposes to elect Briggs Morrison to board

TIPRANKS
·
07 Jan

Press Release: CRISPR Therapeutics Proposes New Appointment to the Board of Directors

Dow Jones
·
07 Jan

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
06 Jan

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
06 Jan